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Abstract
Background: Diabetes mellitus (DM) is a complex disease with alterations in metabolic and inflammatory markers.
Stillman Salgado rats (eSS) spontaneously develop type 2 DM by middle age showing progressive impairment of
glucose tolerance with hyperglycemia, hypertriglyceridemia and hyperinsulinemia. We analyzed the effects of
supplementation of ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) with or without nordihydroguaiaretic acid
(NDGA) added, an antioxidant and lipoxygenase inhibitor, on metabolic and inflammatory parameters in eSS rats to
evaluate whether they can delay development and/or prevent progression of DM.
Methods: After weaning, eSS rats received, intraperitoneally, once amonthω-3 (EPA 35% andDHA 40%–6.25mg/Kg) orω-6
(90% arachidonic acid- 6. 25mg/Kg) for twelvemonths. Two additional groups of rats received 1.9mg/kg NDGA added toω-3
andω-6 fatty acids. Blood samples were collected at day 40, and at the end of the 6thmonth and 12thmonth of age to
determine plasma triglycerides (TGs), total plasma fatty acids (FA), A1C hemoglobin (HbA1C), C-reactive protein (CRP), gamma
glutamyl transpeptidase (GGT), lipo and hydro peroxides, nitrites and IL-6 (in plasma and liver, kidney, and pancreas) and
underwent oral glucose tolerance test (OGTT) as well. Wistar and eSS rats that received saline solutionwere used as controls.
Results: Plasma lipids profile, TG, fasting and post-prandial blood glucose levels, and glycosylated HbA1C showed significant
improvements inω-3 andω-3 + NDGA treated animals compared to eSS control group.ω-3 andω-3 + NDGA groups showed
an inverse correlationwith fasting blood glucose and showed lower plasma levels of GGT, TG, and CRP. eSS rats treatedwithω-
3 LCPUFAs showed reduced level of inflammatory and oxidative indices in plasma and liver, kidney and pancreas tissues in
comparisonwith eSS control (non-treated) andω-6 treated groups.
Conclusions: eSS rats are a useful model to study type 2 DM pathophysiology and related inflammatory indices. ω-3 +
NDGA supplementation, at the doses tested, ameliorated inflammatory, metabolic and oxidative stress markers studied.
Keywords: Type 2 diabetes, eSS rats (Stillman Salgado rats), PUFAs, Chronic inflammation, Oxidation process, Plasma
triglycerides, Nordihydroguaiaretic acid
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Background
DM is a complex disease in which alterations in metabolic
and inflammatory indices including perturbations in the
metabolism of glucose, lipids and proteins occur. Perturba-
tions in the oxidative cycle and cellular stress and alter-
ations in glucose metabolism result in an elevation of
inflammatory markers: interleukins-2 and 6 (IL-2 and IL-
6), leukotrienes (LTs such as LTB4), and C-reactive protein
(CRP) [1]. The increasing incidence of DM not only im-
pacts the health of the affected individual but also en-
hances the cost of health care and has implications for
political, economic, and social issues of the society [2]. DM
is estimated to affect about 366 million by 2030. DM and
obesity have common pathophysiological pathways that
may occur due to inadequate physical activity and con-
sumption of high-calorie/high-fat food intake that results
in insulin resistance and metabolic syndrome [3]. It has
been reported that an imbalance in the metabolism of ω-3
and ω-6 long-chain polyunsaturated fatty acids (LCPUFAs)
occurs in obesity, insulin resistance, metabolic syndrome,
and DM [4, 5].
eSS rats are a strain derived from inbred Wistar rats,
which develop spontaneously type 2 DM without obesity
that resembles closely type 2 DM seen in adult humans.
Type 2 DM is more severe in male eSS rats and they sur-
vive an average of 18 months if insulin is not administered
to control hyperglycemia. In early stages of the develop-
ment of DM, eSS rats show glucose intolerance with hyper-
insulinemia and dyslipidemia. These findings are similar to
those observed in humans with type 2 DM [6–8].
In the present study, we administrated ω-3 (fish oil rich
in EPA 35% and DHA 40% obtained from Natufarma®
Argentina) and ω-6 (AA 90% Sigma®) PUFAs with and
without nordihydroguaiaretic acid (NDGA), and studied
their effects on metabolic and inflammatory indices.
NDGA is a natural product extracted and isolated from
native shrub specie of Larrea sp. NDGA inhibits predom-
inantly lipoxygenase (LOX) and partially, cyclooxygenase
(COX) pathways with powerful anti-inflammatory, anti-
apoptotic and anti-oxidative actions [9, 10]. It is believed
that inhibition of LOX and COX pathways and adminis-
tration of anti-inflammatory compounds may be of benefit
in type 2 DM especially in preventing long-term complica-
tions of DM especially those related to inflammatory and
oxidative stress related complications that are generally
mediated by IL-6, tumor necrosis factor-α (TNF-α), pros-
taglandin E2 (PGE2, derived from arachidonic acid), react-
ive oxygen species (ROS) and other related molecules. It
has been postulated that ω-3 PUFAs are capable of sup-
pressing IL-6, TNF-α, PGE2, and ROS production and
thus, may be of benefit in type 2 DM. Hence, we studied
the effect of ω-3 PUFAs with and without NDGA on vari-
ous inflammatory and oxidative stress indices in eSS rats.
We have chosen intraperitoneal route to administer
PUFAs and NDGA because it allows to deliver the exact
amount of the desired substance without loss or uninten-
tional spills and to bypass possible influences of gut
enzymes, gut microbiota and dietary fiber among others
on the chosen chemicals that are employed to study
[5, 11–16].
The results of this study showed that intraperitoneal
administration of ω-3 LCPUFAs and, especially that of a
combination of ω-3 + NDGA decreased oxidative and in-
flammatory markers and improved metabolic parameters
in this eSS model of spontaneous type 2 DM.
Results and discussion
Weight
It was observed that breast-fed eSS rats had a higher
body weight compared to Wistar rats till the age of
6 months. But, this difference in their body weights dis-
appeared at 6th and 12th months (Fig. 1).
Plasma lipid profile
Quantitative and qualitative differences in the lipid pro-
file of experimental groups are shown in Figs. 2 and 3,
and in Tables 1 and 2. The eSS rats showed significant
alterations in their lipid profile as has been described
previously [10, 11]. Clinical, experimental and epidemio-
logical evidences established that lipid metabolism ab-
normalities are associated with diseases such as coronary
artery disease, cancer and diabetes mellitus [17]. Our re-
sults showed total saturated fatty acids (SFA) values are
significantly higher in the ω-6 group compared to the ω-
3 group. Total monounsaturated FAs (MUFAs) were sig-
nificantly higher in the ω-3 group in comparison to eSS
control and ω-6 groups. Total ω-3 LCPUFAs were sig-
nificantly higher in the ω-3+NDGA group, whereas
gamma-linolenic acid (GLA 18:3n6) was significantly
lower in the ω-3 group compared to eSS control and ω-
6 groups.
It is seen from the results of the present study that
linoleic acid (LA, 18:2 ω-6) levels are higher while those
of 20:3 ω-3, AA (20:4 ω-6), EPA (20:5 ω-3) and DHA
(22:6 ω-3) are lower in eSS rats compared to Wistar
control. Thus, in general, healthy Wistar control rats
had much higher levels of long chain PUFAs compared
to diabetic eSS rats. These results are similar to those
seen in patients with type 1 and type 2 DM who are
known to have lower levels of AA, EPA and DHA and
altered ratios ω-6/ω-3 [18–20] compared to healthy con-
trols. The increase in LA and decrease in its product AA
in eSS rats compared to Wistar control indicates that
the activities of Δ6 and Δ5 desaturases is altered in the
eSS rats. It is surprising to note that plasma AA levels
did not increase in eSS rats treated with ω-6, whereas it
(AA) was decreased in ω-3 and ω-3 + NDGA groups.
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These results could be explained, at least in part, by
defective metabolic PUFAs pathway. Linoleic acid (LA,
18:2 ω-6) and α-linolenic acid (ALA, 18:3 ω-3), cannot
be synthesized by mammals. Once incorporated by the
cells, they can be desaturated and elongated to produce
long chain PUFAs of the same family. Under normal
conditions, ALA is preferentially desaturated and elon-
gated to form eicosapentaenoic acid (EPA, 20:5 ω-3) and
docosahexaenoic acid (DHA, 22:6 ω-3), whereas LA is
also similarly desaturated and elongated to form γ-
linolenic acid (GLA, 18:3 ω-3), dihomo-GLA (DGLA,
20:3 ω-6) and arachidonic acid (AA, 20:4 ω-6). It is
known that both LA and ALA belonging to different
families of PUFAs compete for the same set of enzymes
of desaturases and elongases [18–20]. Changes in the ac-
tivities of Δ6 and Δ5 desaturases in DM has been corre-
lated to the lower content of AA and higher content of
LA in almost all the tissues except brain [21, 22]. In ex-
perimental animals induced to develop type 2 DM and
patients with type 2 DM, the changes in the activities of
Δ6 and Δ5 desaturases have been variable [22–25], but
data indicate that type 2 DM (at least in patients with
long standing disease and poor glycemic control) nega-
tively affects Δ5 desaturases activity and ω6/ω3 PUFAs
balance [18, 26].
Administration of LCPUFAs (AA, EPA and DHA) to
eSS rats can overcome this blockade in the PUFAs meta-
bolic pathways and restore the PUFAs profile to normal
as seen in healthy Wistar rats. Our results of the present
study suggest that the enhanced levels of LA seen in eSS
rats could be restored to levels seen in healthy Wistar
rats by treating with AA (ω-6 and ω-6 + NDGA groups
of the present study), and is in accordance with the pre-
vious results [19, 27]. The LCPUFAs derived from LA
and ALA serve as precursors to several biologically ac-
tive molecules such as prostaglandins (PGs), leukotrienes
(LTs), thromboxanes (TXs), lipoxins (LXs), resolvins,
protectins and endocannabinoids. These metabolites
have potent pro-inflammatory or anti-inflammatory ac-
tions [28, 29]. The relative proportions of LCPUFAs in
cell membranes, as well as cell type, are the primary fac-
tors that regulate the formation of some of these bio-
active lipid metabolites. It is likely that eSS rats treated
with ω-3 LCPUFAs may lead to the formation of some
of these anti-inflammatory metabolites such as lipoxins,
resolvins and protectins [28, 29]. This assumption is
supported by our recent studies that showed that lipoxin
A4, an anti-inflammatory product formed from AA has
anti-diabetic actions in chemical-induced diabetic animal
models [27].
In the present study, supplementation of ω-3 and ω-6
LCPUFAs to eSS diabetic rats did not reach levels of
total PUFAs as detected in the plasma of healthy Wistar
rats (Fig. 2 and 3). Despite this, evaluation of inflamma-
tory and oxidative stress markers showed significant
decrease in their concentrations.
Metabolic parameters
Both fasting blood glucose (FBG) and post-prandial
values in all the eSS groups were higher compared to
the control Wistar group at the end of 6 and 12 months
of age. Oral glucose tolerance test (OGTT) revealed that
ω-3 and ω-3 + NDGA groups showed lower glycemic
levels compared to other groups. In addition, HbA1C
TREATMENTS
Fig. 1 Weight changes (in grams) in eSS male rats at the end of breast feeding, 6 months and 12 months of age. *Indicate significant difference
of Wistar at breastfeed p<0.05
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values were also found to be lower in ω-6 LCPUFA with
or without NDGA groups compared to the untreated
eSS control (Figs. 4 and 5). Addition of NDGA to ω-6
group also showed lower blood glucose levels in the
OGTT test (Fig. 4). Blood TG levels were normal
(ranged <150 mg/dl) in Wistar group, but its levels were
higher at the end of 6 months onwards in all the eSS
groups. eSS rats that received ω-6 LCPUFA (±NDGA)
and eSS control groups showed higher TG levels,
whereas ω-3 groups (±NDGA) had much lower levels
(see Fig. 6), this fact is similar to that observed in pa-
tients with type 2 DM [11]. Plasmatic values of choles-
terol were similar between the experimental groups and
remained within normal values (data not show).
eSS rats develop type 2 DM at 6 months of age with a
significant increase of A1C (31% above reference values)
at the end of 12 months of age [19]. Glycosylated Hb
(A1C) was measured on pre OGTT blood sample tests.
Chronic elevation of HbA1c, an indicator that persistent
hyperglycemia is present, has been strongly linked to
higher mortality and poor prognosis in DM [30]. In the
eSS control group, plasma TG levels were significantly
increased prior to the development of DM. Higher
plasma TG levels play a major role in lipotoxicity and
modulate insulin sensitivity [31, 32]. Inflammatory and
oxidative markers such as CRP and GGT were also sig-
nificantly increased at 6 months of age in eSS rats even
before an increase in fasting hyperglycemia occurred,
suggesting that hyperlipidemia and pro-inflammatory
events occur much before the development of clinical
DM in the eSS model. This implies that insulin resist-
ance seen in type 2 DM could be linked to alterations in
oxidative stress and pro-inflammatory events. In ω-3
treated eSS group, plasma saturated FAs were signifi-
cantly lowers as shown in Table 1. In addition, a signifi-



















Fig. 2 Plasmatic total fatty acids profile by GLC in experimental groups of rats at 12th month of age, SFA (saturated fatty acids), MUFAs (mono














Fig. 3 Plasmatic PUFAs ω 3 and ω 6 levels by GLC at 12th month of age in experimental groups of rats
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was observed. HbA1c was significantly lower in both ω-
6 and ω-3 LCPUFAs supplemented groups (23% in ω-3
groups and 26% in ω-6 groups, respectively) compared
to Wistar controls, suggesting that the observed anti-
inflammatory and antioxidant effects of ω-3 supplemen-
tation could result in an increase in insulin sensitivity as
a result of enhanced expression of GPR120 (G-protein
coupled receptor 120 is a protein that is encoded by the
GPR120 gene is a member of the rhodopsin family of G
protein-coupled receptors). GPR120 mediates the anti-
inflammatory and insulin-sensitizing effects of omega 3
fatty acids in the pancreatic beta cells and other target
tissues such as liver, kidney, adipose tissue, and muscle.
This could lead to increased glucose uptake, lipid storage
and decreased circulating free FA [33, 34].
Inflammatory parameters
Wistar rats showed normal plasma high sensivity C re-
active protein (hs-CRP) values at the end of 12 months,
while hs-CRP was significantly higher in the eSS control
and ω-6 groups (Fig. 7). eSS control, ω-3 and ω-6 +
NDGA groups showed increase in plasma GGT, however
ω-3 + NDGA treatment resulted insignificant fall in their
levels compared to the eSS control (Fig. 8). Similar
Table 2 Results of coefficient variance of total plasma fatty acids profile of experimental groups (Multivariate descriptive test T)
PARAMETER eSS control ω6 ω6 + NDGA ω3 ω3 + NDGA Wistar Control
p 0.0095 0.0229 0.0068 0.0112 0.0009 0.0003
COEF OF VARIANCE 145.14% 169.61% 153.45% 149.19% 147.34% 93.85%
SE 1.8 2.1 1.9 1.9 1.8 1.3
eSS control: Stillman Salgado rats without treatment; Wistar: non eSS rats without treatment. ω Groups: different PUFAs ω-3 and ω -6 treatments with or without
NDGA (nordihydroguaiaretic acid). A value of p<0.05 was considered as significant
Table 1 Fatty acid composition in the plasma at the end of 12th month of age in eSS, Wistar and ω6 and ω3 LCPUFA
supplemented eSS rats (%)
FATTY ACID eSS control SDM ω6 SDM ω6 + NDGA SDM ω3 SDM ω3 + NDGA SDM WISTAR non eSS SDM
14:0 0,5 0,2 1,16 0,5 0,9 0,6 0,6 0,05 0,7 0,8 1,6 1,3
16:0 14,49 4,7 32,26 10,6 26,5 11,7 15,4 0,2 18 8,4 13,4 6,4
18:0 8,14 3,9 12,17 2,7 10,6 0,4 6 1,1 6,5 2,4 10,9 2,1
24:0 0,43 0,3 0,3 0,02 0,2 0,007 0,2 0,02 0 0 1,9 0,3
SFA 23,56* 9,1 45,89*# 13,82 38,2*# 12,7 22,2*# 1,37 25*# 11,6 27,9# 10,1
14:1 n9 0,34 0,2 0,58 0,04 1,1 0,3 0,3 0,05 1,3 1,1 1,5 0,01
16:1 n7 5,18 4,1 1,66 0,9 6,8 1,5 9,8 0,3 31 1,6 1,3 0,2
18:1 n9 21,5 8,2 14,63 6,6 13,3 4,31 22,3 0,8 13 1,1 12,1 6,1
20:1 n9 0,31 0,2 0,34 0,007 2,2 0,3 0,8 0,1 0 0 5,3 0,4
22:1 n9 0,3 0,3 0,25 0,006 1 0,02 0 0 0 0 2,3 0,1
MUFAs 27,6* 13 17,46*# 7,553 24,5*# 6,43 33,3# 1,25 45,4* 3,8 22,5# 6,81
18:2 n6 23,7 5,8 19,75 0,08 15,2 2,7 27,6 0,1 8,6 1,4 17 9
18:3 n6 5 5,4 1,22 0,002 1,2 0,6 0 0 1,6 0,05 1,4 0,02
18:3 n3 1,5 0,6 0,22 0,001 1,3 0,3 3,9 0,5 13,6 1,5 1,5 0,9
20:2 n6 0,2 0,2 0,2 0.005 1,2 0,06 0,2 0,02 0 0 3,3 0,3
20:3 n3 1,2 0,7 0,08 0,01 1,5 1 8 0,2 2,3 0,5 3,7 0,2
20:4 n6 9,2 3,2 9,2 0,3 6,1 1 0,8 0,02 1,7 0,3 16,2 3,4
20:4 n3 0,1 0,1 0,2 0,01 0 0 2,3 0,05 0 0 3,7 0,2
20:5 n3 0,28 1,02 0,16 0,07 1,25 0,16 0,91 0,7 0,57 0,01 2,04 0,7
22:6 n3 0.0 0 0,2 0,01 1,1 0,3 0,2 0,01 0,2 0,02 5 0,4
22:5 n3 1,1 1,3 1,13 0,01 2,3 0,03 1,4 0,05 3,1 0,4 2,5 0,1
PUFAs 42,2 18,3 32,2* 0,493 29,1* 6,15 44 1,65 31,1* 4,18 54,3 15,22
PUFAs n3 4* 2,9 1,83* 0,036 6,2* 1,63 15,1# 0,81 19,3*# 2,42 16,4# 1,8
PUFAs n6 38,2 14,4 30,37*# 0,39 23,7# 4,36 29# 0,14 12# 1,75 38# 12,72
Values represent means and Standard deviation of the mean (SDM). Values P< 0.05 were considered statistically significant. *Indicate significant difference of
Wistar at 12th month. #Indicate significant difference of eSS control at 12th month
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decrease in the levels of IL-6, nitrites and peroxides was
noted in ω-3 + NDGA group. In all groups that received
ω-3 ± NDGA showed lower values with respect to
peroxides (Fig. 9), nitrites (Fig. 10) and IL-6 (Figs. 11, 12,
13 and 14) compared to eSS rats and ω-6 groups. It is
seen that plasma lipid and hydroperoxides, lipo perox-
ides, nitrites and IL-6 levels in groups that received ω-
3 + NDGA were closer to those seen in Wistar control
group (Figs. 9–14).
In ω-3 + NDGA treated eSS group, a synergistic action
between these compounds reduced TG plasma values
and NF-κB and JNK/AP1 expression by inhibition of
TAK1 (Transforming growth factor β-activated kinase 1)
that results in suppression of production of pro-
inflammatory cytokines [31]. Other possible mechanisms
of the beneficial action of ω-3 + NDGA could be due to
its ability to act on PPAR-alpha and suppress expression
of NF-kB [29]. On the other hand, it is also likely that
TREATMENTS
eSS control NDGA NDGA Wistar
BREASTFEED POST OOTG BG 116,4 107,1 121,7 119,8 118,6 108,2
6TH MONTH POST OOTG BG 200,0 216,3 210,4 197,5 200,7 113,4




























CONTROL eSS NDGA NDGA Wistar
BREASTFEED FASTING BG 124,5 102,4 100,5 95,2 94,2 87,4
6TH MONTH FASTING BG 143,0 132,0 128,9 120,8 118,2 94,8

























Fig. 4 Fasting and Post OGTT blood glucose levels at the end of breast feeding, 6th and 12th months of age in experimental groups of animals,






BREASFEED Hb A1C 5,1 4,8 4,8 4,8 4,8 4,5
6TH MONTH Hb A1C 6,9 5,9 5,9 5,9 5,9 5,0







Fig. 5 Glycosylated hemoglobin (HbA1c) levels at the end of breast feeding period, 6th and 12th month of age in experimental groups of
animal, *Indicate significant difference of Wistar at 12th month p<0.05, #Indicate significant difference of eSS control at 12th month p<0.05
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ω-3 LCPUFAs act on GPR120 receptors as a consequence
of which the expression of GLUT4 receptors is increased
that leads to a decrease in hypertriglyceridemia and hyper-
glycemia by the suppression of inflammatory pathways [35,
36]. GPR120 has also been shown to mediate the anti-
inflammatory and insulin-sensitizing effects of ω-3 LCPU-
FAs and its lack or defincency is responsible for reduced fat
metabolism, thereby leading to obesity and DM [37]. It may
also be noted here that ω-3 LCPUFAs may bring about
their beneficial actions independent of GPR120 [38].
This is supported by the observation that the ω-3 treated
eSS group with or without NDGA showed a significant re-
duction (>40%) in blood CRP at 12 months of age com-
pared to the eSS control group. CRP is a sensitive pro-
inflammatory marker, closely related to circulating IL-6, a
cytokine that is released by activated macrophages, endo-
thelial cells, adipocytes, muscle cells and T-lymphocytes to
stimulate immune response [39]. IL-6 stimulates the
inflammatory and auto-immune processes in many diseases
such as diabetes, atherosclerosis, obesity, and cardiovascular
diseases among others [40]. Results have shown a signifi-
cant reduction in plasma and tissue (liver, kidney and pan-
creas) levels of IL-6 following ω-3 treatment (Figs. 11, 12,
13 and 14) and have reverted to near normal values found
in the Wistar rats (reductions ≥50%). It is also noteworthy
that eSS rats that developed insulin resistance and type
2 DM features showed evidence of systemic inflamma-
tion in the form of significantly elevated IL-6 levels
not only in the plasma but also in various tissues ex-
amined (liver, pancreas and kidney) suggesting that in-
sulin resistance, hyperlipidemia and type 2 DM are
low-grade systemic inflammatory conditions as pro-
posed previously [1, 5, 12, 41–43].
It has been suggested that an imbalance between ω-6/ω-3
LCPUFAs concentrations with a shift towards ω-6 LCPU-
FAs (ω-6 >ω-3) could contribute to the development of
TREATMENTS
Fig. 6 Plasma triglycerides levels at the end of breastfeeding, 6th and 12th month of age in experimental groups of rats, p<0.05, *Indicate

















Fig. 7 Plasmatic CRP levels in experimental groups of rats at 12th month of age, *Indicate significant difference of Wistar p<0.05, #Indicate
significant difference of eSS control at 12th month p<0.05
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TREATMENTS
eSS control NDGA NDGA
WISTAR non
eSS
BREASTFEED GGTP 0,14 0,01 - 0,00 0,01 0,00
6TH MIONTH GGTP 0,11 0,00 0,00 0,00 0,00 0,01


























Fig. 8 Plasma GGT levels at the end of breastfeeding, 6th and 12th month of age in experimental groups of rats
eSS NDGA NDGA Wistar




























































































Fig. 9 Plasmatic levels of Lipo and Hydro Peroxides at 12th month of age in experimental groups of rats, *Indicate significant difference of Wistar
p<0.05, #Indicate significant difference of eSS control at 12th month p<0.05
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systemic low-grade chronic inflammation (SLGCI), which,
in turn, may favor the initiation and perpetuation of endo-
thelial dysfunction, insulin resistance, and consequently the
development of hypertension and type 2 DM [44, 45].
PUFAs of ω-6/ω-3 families compete for the same set of en-
zymes and metabolic pathway, and are essential for the for-
mation of long-chain metabolites like eicosanoids that have
pivotal biological functions [5, 43]. AA, the major ω-6
LCPUFA which is known to be a precursor of predomin-
antly pro-inflammatory eicosanoids (such as PGE2, PGF2α,
TXA2 and leukotrienes) in significant amounts compared
to the formation of less anti-inflammatory eicosanoids de-
rived from ω-3 LCPUFAs, COX and LOX enzimes
metabolize 20-carbons PUFA to produce eicosanoids and
other bioactive lipids, its enzimes have more affinity by ω-3
PUFAs but ω-6 are usually in higher concentrations [5, 11].
Furthermore, PUFAs can also form precursors to anti-
inflammatory compounds such as lipoxins, resolvins, and
protectins. It is generally believed that under normal
physiological conditions a balance is maintained between
Fig. 10 Plasma nitrite levels at the end of the12th month of age in experimental groups of rats, *Indicate significant difference of Wistar at 12th
month, #Indicate significant difference of eSS control at 12th month, p<0.05
Fig. 11 Plasma IL6 levels at the end of the12th month of age in experimental groups of rats, *Indicate significant difference of Wistar, #Indicate
significant difference of eSS control at 12th month, p<0.05
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pro- and anti-inflammatory products formed to maintain
normal homeostasis and suppress the initiation of low-
grade systemic chronic inflammation in DM [5, 43]. In this
context, it is noteworthy that ω-3 LCPUFAs induce their
anti-inflammatory effects by acting on the GPR120 and
Toll-like receptors (TLRs) [5, 28, 29, 36–38, 42, 43] that re-
sults in the suppression of formation of TNF-α and other
pro-inflammatory cytokines especially in macrophages,
adipocytes and hepatocytes [5, 28, 29, 43]. As a result,
pro-inflammatory events are switched off or suppressed.
In addition, NDGA is a potent antioxidant [9, 46, 47], and
has potent anti-inflammatory actions by inhibition of
COX-2 and LOX enzymes that results in decreased pro-
duction of pro-inflammatory prostaglandins and leukotri-
enes. Hence, it is expected that a combination of ω-3 +
NDGA may be more effective in suppressing
Fig. 12 IL6 levels in pancreas of experimental rats at the end of the12th month of age, *Indicate significant difference of Wistar, #Indicate
significant difference of eSS control at 12th month, p<0.05
Fig. 13 Liver IL6 levels at the end of the12th month of age in experimental groups of rats, *Indicate significant difference of Wistar, #Indicate
significant difference of eSS control at 12th month, p<0.05
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inflammatory events as observed in the present study (see
Figs. 7–14).
Oxidative markers such as plasma lipo- and hydro-
peroxides and nitrites showed pronounced reductions
when ω-3 + NDGA were administrated that were very
close to the normal values seen in the non-
diabetic Wistar rats. On the other hand, these values
were closer to those seen in eSS control rats in the ω-6
treated groups. The ω-3 + NDGA treated eSS group
showed decreased GGT at 6 and 12 months of age
compared to ω-6 and eSS control groups. ω-3 and ω-6
LCPUFAs treated eSS groups, when co-supplemented
with NDGA, showed much lower levels of GGT, CRP,
IL-6, and peroxides at the time of fasting. This implies
that NDGA supplementation has significant beneficial
action in decreasing and attenuating inflammatory re-
sponse and oxidative stress in this model.
Correlation study
Metabolic (TG), oxidative stress (GGT) and inflamma-
tory parameters (CRP) were assayed at fasting and post-
prandial state after glucose administration that showed
increased values in the eSS control whereas these indices
were normal in Wistar control rats. ω-3 group (with or
without NDGA addition) showed much lower values of
GGT, TGs, CRP, IL-6 and lipid peroxides compared to
ω-6 and eSS control groups (Table 3).
GGT activity, which has an important role in SLGCI,
was positively and significantly correlated to CRP. On the
other hand, ω-6 treated group showed increased GGT and
TG levels. CRP values presented a negative correlation,
for both FBG and PBG in these groups. GGT and CRP
levels decreased when NDGA was supplemented.
Plasma TGs did not change with the addition of
NDGA and in fact, a positive correlation was found
both for FBG and PGB. In both ω-3 and ω-6 LCPU-
FAs treated groups without NDGA supplementation,
GGT and CRP increased at the time of fasting but
decreased at postprandial stage as recorded by correl-
ation tests. Based on these results, it is suggested that
supplementation of NDGA along with ω-3 could be
beneficial to suppress insulin resistance, oxidative
stress and inflammatory responses, at least in this
experimental model of type 2 DM [48].
Previous works showed that both ω-3 and ω-6
LCPUFAs prevent alloxan-induced apoptosis of RIN
(rat insulinoma) cells in vitro and alloxan-induced
type 1 DM that is not mediated by both COX and
LOX inhibitors indicating that prostaglandins and
leukotrienes do not have any role in this cytoprotec-
tive action of fatty acids [49–52]. These results imply
that a deficiency of ω-3 EPA and DHA and ω-6 AA
may predispose to the development of DM. Type 1
and type 2 DM patients, as mentioned above, have
decreased concentrations of AA, EPA and DHA and
other unsaturated fatty acids in their plasma [53, 54]
lending further support to the concept that unsatur-
ated fatty acids may have a significant role in the
pathobiology of DM. In a recent study, we noted
that anti-inflammatory product of AA, lipoxin A4
(LXA4) concentrations are low in the plasma of pa-
tients with type 2 DM [55] suggesting that one
mechanism by which LCPUFAs are able to prevent
DM, or mitigate their complications, is by producing
LXA4 and other similar anti-inflammatory products.
Fig. 14 IL6 levels in kidney of experimental rats at 12th month of age, *Indicate significant difference of Wistar, #Indicate significant difference of
eSS control, p<0.05
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Conclusions
In the spontaneous eSS rat type 2 DM model, as shown
in the present study, ω-3 LCPUFAs are more effective
than ω-6 in suppressing pro-inflammatory and oxidative
stress markers seen in DM. These results are in agree-
ment with the evidence that diets rich in ω-6 LCPUFAs
such as red meat enhances circulating IL-6 levels and
causes hyperglycemia and hyperlipidemia contributing
to insulin resistance [56], though this is still debated.
Hence, it is essential that a balance is maintained be-
tween ω-6/ω-3 LCPUFAs by consuming more amounts
of ω-3 (mainly present in marine fish such as EPA and
DHA) in the diet or by oral supplementation of fish oil
capsules that may aid in suppressing inflammatory and
oxidative stress indices and enhance insulin sensitivity
and improve endothelial function [5, 43]. In this context,
it is interesting to note that supplementation of both ω-
3 and ω-6 PUFAs especially in combination with NDGA
(while ω-6 PUFAs alone failed) inhibited hepatic IL-6
levels compared to eSS control (see Fig. 13) and these
results are in line with the previous report that ω-3
PUFAs significantly reduces liver oxidative stress in-
duced by high fat diet [57]. In addition, the observation
that addition of NDGA has accentuated the beneficial
actions of both ω-3 and ω-6 PUFAs in the presence of
NDGA is rather interesting. Though we interpreted this
beneficial action of NDGA in terms of its LOX inhibi-
tory property, we are aware to the possibility that NDGA
might be bringing about its useful actions by virtue of its
antioxidant properties which are related to its ability to
modulate Nrf2/ARE (nuclear factor erythroid 2-related
factor 2/antioxidant response element) antioxidant path-
way [58].
In a similar fashion, the beneficial actions of ω-3 and
ω-6 PUFAs observed in the present study may also be
due to the ability of these PUFAs to bypass the inhibi-
tory action of high fat diet on enzymes desaturases [59]
and upregulation of PPARs and inhibition of NF-kB by
these unsaturated fatty acids [60]. Thus, the beneficial
actions of various PUFAs are rather complex that need
to be dissected in future studies
In the present study, we observed that NDGA supple-
mentation along with ω-3 LCPUFAs is better suited to
modify metabolic and inflammatory parameters that
may be beneficial in restricting the progression of DM in
eSS rats and its associated complications. The beneficial
actions seen with the addition of NDGA along with ω-3
and possibly with ω-6 LCPUFAs could be related to the
preferential formation of anti-inflammatory com-
pounds from EPA and DHA and AA such as lipox-
ins, resolvins and protectins as proposed previously
[5, 43]. However, these proposals need confirmation
in future studies.
On the basis of the present results, we conclude
that eSS rat type 2 DM model is useful to conduct
studies as to the involvement of PUFAs and their me-
tabolites in the pathophysiology of type 2 DM and




A total of 105 male rats were used, of which 15 were
Wistar and 90 were eSS. After weaning, forty days
old rats were randomly assigned to different groups
as shown in Table 4. All animals were fed ad libitum
Table 3 Treatment correlation test (R2)
GROUP PARAMETER GGTP TG CRP Plasma
IL6
lipo Peroxides
eSS CONTROL FASTING BLOOD GLUCOSE 0,93 0,66 0,45 0,88 0,24
POSTPRANDIAL BLOOD GLUCOSE 0,25 0,89 0,81 0,94 0,54
ω6 FASTING BLOOD GLUCOSE 0,70 0,74 −0,70 0,32 0,65
POSTPRANDIAL BLOOD GLUCOSE −0,65 −0,13 −0,76 0,28 0,84
ω6 + NDGA FASTING BLOOD GLUCOSE −0,78 0,67 −0,14 −0,12 0,17
POSTPRANDIAL BLOOD GLUCOSE −0,51 0,84 −0,60 −0,08 −0,39
ω3 FASTING BLOOD GLUCOSE 0,41 −0,20 −0,60 −0,20 0,22
POSTPRANDIAL BLOOD GLUCOSE −0,55 0,65 0,15 0,16 −0,18
ω3 + NDGA FASTING BLOOD GLUCOSE −0,43 −0,70 −0,32 −0,44 −0,36
POSTPRANDIAL BLOOD GLUCOSE 0,22 −0,23 −0,27 −0,32 −0,20
WISTAR FASTING BLOOD GLUCOSE −0,70 0,84 0 0,11 0,18
POSTPRANDIAL BLOOD GLUCOSE −0,86 0.14 −0,29 0,16 0,12
n = 90 males rats (eSS control n = 10; ω-6 n = 21; ω-6 + NDGA n = 14; ω-3 n = 29; ω-3 + NDGA n = 16; Wistar rats non eSS n = 15) eSS control: Stillman Salgado rats
without treatment; Wistar: non eSS rats without treatment. ω Groups: different PUFAs ω-3 and ω-6 treatments with or without NDGA (nordihydroguaiaretic acid)
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with chow diet. Treatments were given once in a
month for twelve months. All experimental animals
received 0.40 ml (total volume) of isotonic saline so-
lution (SS) added with PUFAs dissolved in 0.5% of
ethanol and NDGA, as detailed in Fig. 4. Doses used
were selected based on previous experiments and
published literature [61]. All biochemical studies were
performed at day 40 (before the start of PUFAs treat-
ment) designed as breastfeeding weaning period, it
was previously suggested that both obesity and type 2
DM may have their origins in the perinatal period,
and at the end of 6 and 12 months of age [62, 63].
Wistar and a set of eSS rats received only saline solu-
tion formed the control groups. Blood samples were
obtained from tails puncture of the animals for bio-
chemical studies. After extraction, whole blood under-
went centrifugation at 1500 RPM by 10 min and
sodium citrate (70%) was used as anti-coagulant.
Samples were kept at −80 °C freezer. This is sup-
ported by the results of the present study shown in
Fig. 4, where it is seen that fasting plasma glucose
levels estimated on day 40 (breastfeeding weaning
period) are higher in control eSS rats compared to all
other groups.
Blood glucose was assayed in the venous blood
with a glucometer (Accu-chek Performa®) monthly.
Glycosylated Hemoglobin (A1C) was estimated by
A1c Now ® (Bayer) meter. Serum triglyceride (TG)
was assayed by enzymatic colorimetric method.
Plasma ultra-sensitive CRP (hs-CRP), lipo- and -hy-
dro peroxides, nitrites, and plasma gamma-glutamyl
transpeptidase (GGT) were determined by colorimet-
ric methods [64]. IL-6 levels were measured by
ELISA (DO 450 and 570 nm) at 12 months of age in
plasma and organs samples (as per tissue weight). At
the end of 12 months, rats were euthanized by over-
doses of isofluorane and tissue samples were ob-
tained, homogenized, and processed for GLC, IL-6
determination and other assays.
Oral glucose tolerance test (OGTT)
Animals were fasted for 8 h prior to this test. Fasting
blood sample was obtained for glucose estimation and a
second sample was obtained 2 h after the administration
of oral glucose solution (1.75 g/Kg).
Total plasma fatty acids profile determined by Gas
chromatography
The lipids were extracted by Folch’s method and methyl-
ated with sodium methoxide. The separation, quantifica-
tion and identification of fatty acid methyl esters
(FAME) was performed using a capillary column (BPX
20 m longitude, 0.25 mm ID, 0.25 μm film, SUPELCO®,
USA) in a Clarus 500® (Perkin-Elmer) gas chromato-
graph. The FAMEs were identified using a commercial
standard (Nu-check®, USA). All values are expressed as
% Area of total.
Statistical analysis
The results are expressed as mean ± SE. Comparisons
between multiple groups were performed by one-way
ANOVA or Kruskall-Wallis test followed by Dunn’s
post hoc test. The paired Student’s t test was used to
analyze results of blood glucose test. Correlations be-
tween groups were determinate by Pearson Test, ana-
lysis of covariance and correlation test. Statistical
significance was P < 0.05. All statistical tests were per-
formed using INFOSTAT 3.1 and GRAPHPAD PRISM
5 software.
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